Chinese Medical Sciences Journal ›› 2021, Vol. 36 ›› Issue (1): 57-65.doi: 10.24920/003737

• 综述 • 上一篇    下一篇

肝细胞癌靶向治疗研究进展

陈琼,阳学风()   

  1. 南华大学附属南华医院消化内科,湖南衡阳 421002,中国
  • 收稿日期:2020-03-06 接受日期:2020-05-11 出版日期:2021-03-31 发布日期:2021-04-14
  • 通讯作者: 阳学风 E-mail:yxf9988@126.com

Research Progress in Targeted Therapy of Hepatocellular Carcinoma

Qiong Chen,Xuefeng Yang()   

  1. Department of Gastroenterology, the Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan Province 421002, China
  • Received:2020-03-06 Accepted:2020-05-11 Published:2021-03-31 Online:2021-04-14
  • Contact: Xuefeng Yang E-mail:yxf9988@126.com

摘要:

肝细胞癌(Hepatocellular carcinoma,HCC)是常见的恶性肿瘤之一,治疗手段有限。随着肝癌发生发展过程中关键基因和信号通路认识的深入,一些高选择性、低毒性的靶向药物不断问世,为晚期肝癌的治疗带来了多种选择。本文综述了肝细胞癌靶向治疗的代表性药物和潜在靶点的研究进展。

关键词: 肝细胞癌, 靶向治疗, 基因, 信号通路, 药物

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common malignancies, and its treatment is limited. With the understanding of key genes and signaling pathways in the occurrence and development of HCC, targeted drugs with high selectivity and low toxicity have been developed continuously, bringing a variety of options for the treatment of advanced HCC. In this article, the research progress on representative drugs of targeted therapy and potential therapeutic targets for HCC are reviewed.

Key words: hepatocellular carcinoma, targeted therapy, genes, signaling pathway, drug

基金资助: 湖南省卫生计生委科研课题(A2017015)

Copyright © 2018 Chinese Academy of Medical Sciences. All right reserved.
 
www.cmsj.cams.cn
京公安备110402430088 京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health & Family Plan Commission of PRC

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 

E-mail: cmsj@cams.cn  www.cmsj.cams.cn

Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1